Hot Deals:
adtech 70.00 (-4.11 %) agarwal bolts 1,200.00 (0.00 %) amol minechem 601.00 (0.17 %) anand i-power 20.00 anglo french drugs 745.00 (-0.67 %) apl metals 40.00 (-2.44 %) arkfin investments 50.00 arohan 150.00 (3.45 %) assam carbon 220.00 (2.33 %) auckland international 129.00 (-0.77 %) av thomas 16,800.00 (0.00 %) axles 500.00 (2.04 %) balmer lawrie 202.00 (1.00 %) bharat hotels 310.00 (3.33 %) bima mandi 235.00 (-2.08 %) bira 600.00 (0.84 %) boat 1,325.00 (-1.85 %) c & s electric 600.00 (1.69 %) cable corporation 13.00 (-0.76 %) capgemini 11,500.00 (0.88 %) care health 178.00 (-0.56 %) carrier aircon 525.00 (-1.87 %) cial 285.00 (1.79 %) csk 178.00 (-1.66 %) dalmia refract 255.00 (-1.92 %) dfm foods 467.00 dsp merrill lynch 1,000.00 east india pharma 39.00 (-2.50 %) eaton fluid 425.00 (2.66 %) electronica plastic 2,100.00 (-0.99 %) elgi ultra 400.00 elofic 2,050.00 (-0.97 %) esl steel 46.00 (2.22 %) fincare business 72.00 (2.86 %) fincare sfbl 202.00 (1.00 %) finopaytech 154.00 (-1.28 %) flipkart india 231,001.00 (0.00 %) frick india 15,800.00 (3.95 %) gkn driveline 1,330.00 (-2.85 %) go digit general insurance ltd 354.00 (1.14 %) godavari bio 71.00 (1.43 %) goodluck defence 235.00 (-0.42 %) group pharma 300.00 gynofem healthcare 81.00 (1.25 %) hdb financial 1,060.00 (0.95 %) hdfc ergo 370.00 (1.70 %) hdfc securities 11,100.00 (-1.77 %) hella india 810.00 (1.25 %) hero fincorp 1,650.00 (0.61 %) hexaware 970.00 (2.11 %) hicks 1,450.00 (2.11 %) hira ferro 180.00 (2.86 %) honeywell electrical 4,700.00 (2.17 %) ikf finance 243.00 (1.25 %) incred financial 9.90 (-1.00 %) incred holdings 160.00 (3.23 %) india carbon 1,155.00 (-1.70 %) india exposition 145.00 (3.57 %) indian potash 3,100.00 (-1.59 %) indo alusys 25.75 (-0.96 %) indofil 790.00 (0.13 %) infinite computer 405.00 (1.25 %) inkel 21.00 (-4.55 %) ixigo 141.00 (-1.40 %) jana small finance bank 75.00 kel 625.00 (1.63 %) kial 122.00 (-2.40 %) klm axiva 15.00 (-1.32 %) kurlon limited 1,250.00 (2.46 %) lava 65.00 (-7.14 %) mahindra rural mrhfl 100.00 manipal housing 74.00 (2.07 %) manjushree technopack 1,333.00 (-1.26 %) martin & harris 1,030.00 (0.98 %) merino 3,300.00 (1.54 %) minosha 282.00 (0.71 %) mitsubishi heavy 207.00 (-0.48 %) mkcl 430.00 (2.14 %) mobikwik 560.00 (-1.75 %) mohan meakin 1,900.00 (-1.30 %) mohfl 13.25 (1.92 %) msei 1.22 (1.67 %) msil 35.00 (-2.78 %) nayara energy 500.00 (3.09 %) nayara energy ncd 305.00 (1.67 %) ncdex 275.00 ncl buildtek 275.00 (3.77 %) ncl holdings 85.00 (3.66 %) nsdl 810.00 (1.25 %) nse 4,600.00 (1.10 %) orbis financial 295.00 (1.03 %) oswal minerals 60.10 (-1.48 %) otis 3,770.00 (0.53 %) oyo 45.00 (-2.17 %) panasonic appliances 211.00 (0.48 %) paymate india 525.00 (2.14 %) pharmeasy 9.90 (-1.00 %) pharmed limited 480.00 (2.13 %) philips domestic 590.00 (0.85 %) philips india 910.00 (-1.09 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 275.00 (-1.79 %) rapido 16,650.00 (0.03 %) rasoi 31,500.00 (0.32 %) reliance gic 480.00 (1.05 %) resins plastics 415.00 (-1.89 %) ring plus aqua 530.00 (0.95 %) rrl 1,275.00 (2.00 %) rrp s4e innovation 290.00 (1.40 %) sab miller 375.00 (-1.32 %) sbi amc 1,700.00 (1.80 %) sbi general insurance 620.00 (3.33 %) scottish assam 440.00 (-1.35 %) shriram life 261.00 (0.38 %) sigachi laboratories 36.00 (-2.70 %) signify 1,400.00 (3.70 %) smile microfinance 54.00 (3.85 %) sportskeeda 3,303.00 sterlite power 500.00 (-6.54 %) studds 970.00 (-0.51 %) svsml 315.00 (2.94 %) swiggy 350.00 (1.45 %) t stanes 770.00 (1.99 %) tata capital 1,100.00 (0.92 %) teesta agro 77.00 (-6.21 %) trl krosaki 1,275.00 (-1.16 %) urban tots 60.00 (15.38 %) utkarsh coreinvest 290.00 (1.75 %) vadilal dairy 10.00 vikram solar 272.00 (0.74 %) waree energies 2,070.00 (0.98 %)
×

STERLIN BIO Annual Reports, Balance Sheet and Financials

Sterling Biotech Limited (Sterling Biotech) Return Comparision with Primex 40 Index

Periods 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years All Time
Primex-40
Sterling Biotech Limited

STERLING BIOTECH Limited Balance Sheet (Rs In lakhs)

PARTICULARS

2017

2016

2015

ASSETS

 

 

 

Non-current assets

 

 

 

Property, plant and equipment

2,72,629.18

2,96,455.46

3,27,384.21

Capital work-in-progress

2,44,230.25

2,44,974.77

2,27,012.67

Financial assets

 

 

 

Investments

1,58,207.12

1,55,243.63

1,36,648.39

Deferred tax assets(net)

37,958.27

18,007.56

-1,558.13

Other non-current assets

14,142.80

16,238.03

18,857.07

 

7,27,167.62

7,30,919.45

7,08,344.21

Current Assets

 

 

 

Inventories

70,330.16

71,753.03

63,456.54

Financial assets

 

 

 

Trade receivables

4,332.82

4,225.27

18,055.92

Cash and cash equivalents

1,692.81

1,663.88

1,765.92

Other current assets

31,985.80

27,460.53

22,793.32

 

1,08,341.59

1,05,102.71

1,06,071.71

Total assets

8,35,509.21

8,36,022.16

8,14,415.92

EQUITYAND LIABILITIES

 

 

 

Equity

 

 

 

Equity Share capital

2,721.70

2,721.70

2,720.48

Other Equity

1,24,887.44

1,63,652.62

1,94,188.56

Total Equity

1,27,609.14

1,66,374.32

1,96,909.04

Liabilities

 

 

 

Non-current liabilities

 

 

 

Financial Liabilities

 

 

 

Borrowings

3,99,151.90

4,16,607.33

3,36,797.30

Current liabilities

 

 

 

Financial Liabilities

 

 

 

Borrowings

95,820.30

93,243.88

1,10,845.82

Trade Payables

3,789.80

2,233.49

2,469.06

Other Financial Liabilities

2,07,731.17

1,56,249.69

1,64,922.49

Other Current Liabilities

1,406.89

1,313.45

2,472.21

 

3,08,748.17

2,53,040.51

2,80,709.58

Total liabilities

7,07,900.07

6,69,647.84

6,17,506.89

Total equity and liabilities

8,35,509.21

8,36,022.16

8,14,415.92

STERLING BIOTECH Limited Profit& Loss Statement (Rs In LAKHS)

PARTICULARS

2017

2016

 

Revenue from operations

40,018.95

56,053.13

 
 

Other income

397.7

784.95

 

Total income (I)

40,416.64

56,838.08

 

Expenses

 

 

 

Cost of raw material and components consumed

25,860.60

44,437.31

 

Change in inventories of finished goods and work-in-progress

1,485.48

-8,993.27

 

Excise Duty on sale of goods

3,176.39

3,654.11

 

Employee benefits expense

5,440.69

6,610.86

 

Finance costs

36,979.77

41,478.19

 

Depreciation&amortisation

26,354.78

34,514.48

 

Other expenses

2,798.43

3,898.51

 

Total expenses (II)

1,02,096.15

1,25,600.19

 

Profit/(Loss)before exceptional item and tax(I-II)

-61,679.50

-68,762.11

 

Profit/(Loss)before tax

-61,679.50

-68,762.11

 

Tax expense

 

 

 

deferred tax

-20,434.00

-23,715.00

 

Total tax expense

-20,434.00

-23,715.00

 

Profit/(Loss)for the period

-41,245.50

-45,047.11

 

Other Comprehensive Income

 

 

 

Items that will not to be reclassified to profit or loss

 

 

 

Net(loss)/gain on FVTOCI of equity  securities

2,963.61

18,588.27

 

Income tax effect

-483.29

-4,149.32

 

Net other comprehensive income not to be reclassified to profit or loss

2,480.32

14,438.95

 

Total comprehensive income for the period, net of tax

-38,765.19

-30,608.15

 

Earning per equity share [FacevalueofRs.1/-each]

 

 

 

-Basic

-15.15

-16.55

 

-Diluted

-9.52

-10.4

 

STERLING BIOTECH LIMITED Consolidated Cash Flow Statement (Rs In LAKHS)

PARTICULARS

2016

2017

A)Cash flow from operating activities:

 

 

Net Profit before taxation and exceptional items

-61,679.50

-68,762.11

Adjustments for

 

 

-Depreciation/amortization

26,354.78

34,514.48

Interest expenses

36,979.77

41,478.19

Operating profit before working capital changes

1,655.05

7,230.56

Movement in working capital:

 

 

(Increase)/Decrease in Trade Receivables

-107.55

13,830.65

(Increase)/Decrease in Other Receivables

-4,525.27

-4,667.21

(Increase)/Decrease in Inventory

1,422.87

-8,296.49

Increase/(Decrease)in Trade Payable(Current Liabilities)

1,649.75

-723.38

 

94.85

7,374.14

Direct Tax

-

-670.95

Net cash flow(used in)/from operating activities

94.85

6,703.19

B)Cash flows from investing activities

 

 

Sales/(Purchase)of fixed assets

-4,927.79

-8,438.52

Sales/(Purchase)of investments

0.12

-6.97

Net cash flow used in investing activities

-4,927.67

-8,445.49

C)Cash flows from financing activities

 

 

Proceeds from Issue of Preference Shares

5,856.50

34,720.84

Proceeds from Share Premium on issue of shares

-

0

Proceeds/(Repayment)of long term borrowings

35,755.49

24,386.36

Proceeds/(Repayment)of short term borrowings

229.53

-15,988.75

Interest paid

-36,979.77

-41,478.19

Dividend&Dividend Tax

-

-

Net cash(used in)/from financing activities

4,861.75

1,640.26

Net increase/(decrease)in cash & cash equivalents

28.93

-102.04

Cash and cash equivalents at the beginning of the year

1,663.88

1,765.92

Cash and cash equivalents at the end of the year

1,692.81

1,663.88

Certainly, let 's delve into a more detailed point-wise explanation of each section of the Cash Flow Statement for the years 2016 and 2017.

 Cash Flow from Operating Activities:

1. Net Profit before Taxation: In 2016, the company incurred a net loss of Rs. 61,679.50, which increased to Rs. 68,762.11 in 2017.

2. Adjustments for Depreciation/Amortization and Interest Expenses: The company made adjustments for non-cash expenses, such as depreciation and amortization, as well as interest expenses. These adjustments resulted in an operating profit before working capital changes of Rs. 1,655.05 in 2016 and Rs. 7,230.56 in 2017.

3. Working Capital Changes: The movement in working capital involves changes in Trade Receivables, Other Receivables, Inventory, and Trade Payables. Notably, there was an increase in Trade Receivables and Inventory in 2017, reflecting potential challenges in collecting receivables and managing inventory.

4. Direct Tax: In 2017, the company incurred direct tax expenses amounting to -Rs. 670.95, indicating a tax benefit or credit.

5. Net Cash Flow from Operating Activities: The net cash flow from operating activities was Rs. 94.85 in 2016 and significantly improved to Rs. 6,703.19 in 2017. This positive trend suggests improved operational efficiency and cash generation in the latter year.

 Cash Flows from Investing Activities:

1. Purchase/Sale of Fixed Assets and Investments: The company utilized cash for the purchase of fixed assets and investments. In 2017, the cash outflow increased substantially to Rs. 8,445.49, indicating significant investment or expansion activities.

2. Net Cash Flow Used in Investing Activities: The net cash outflow from investing activities was Rs. 4,927.67 in 2016 and increased to Rs. 8,445.49 in 2017, reflecting increased capital expenditure and investment.

 Cash Flows from Financing Activities:

1. Proceeds from Issue of Preference Shares and Share Premium: The company generated cash through the issue of preference shares, with Rs. 5,856.50 in 2016 and Rs. 34,720.84 in 2017. There were no proceeds from share premium in 2016.

2. Long-Term and Short-Term Borrowings: The company generated cash through long-term borrowings in both years, with Rs. 35,755.49 in 2016 and Rs. 24,386.36 in 2017. Short-term borrowings contributed Rs. 229.53 in 2016 and offset by -Rs. 15,988.75 in 2017.

3. Interest Paid: The Company paid interest on borrowings, with amounts of -Rs. 36,979.77 in 2016 and -Rs. 41,478.19 in 2017.

4. Net Cash Flow from Financing Activities: The net cash inflow from financing activities was Rs. 4,861.75 in 2016 and Rs. 1,640.26 in 2017, indicating the net positive impact of financing decisions on cash.

Net Increase/(Decrease) in Cash & Cash Equivalents:

The net increase/(decrease) in cash and cash equivalents was Rs. 28.93 in 2016, reflecting a modest positive impact. However, in 2017, there was a decrease of Rs. 102.04, indicating a reduction in overall cash and cash equivalents during the year.

Cash and Cash Equivalents at the Beginning and End of the Year:

The cash and cash equivalents at the beginning of the year were Rs. 1,663.88 in 2016, increasing to Rs. 1,692.81 by the end of the year. In 2017, the cash and cash equivalents at the beginning of the year were Rs. 1,765.92, decreasing to Rs. 1,663.88 by the end of the year. These figures highlight the company 's liquidity position and its ability to manage cash over time.

Below are the Financial Ratios

PARTICULARS

2017

EBITDA

 -80.49 %

Net worth

 -23.30 %

Debt/Equity Ratio

3.88

Return on Equity

-32.32%

Total Assets

 -0.06 %

Fixed Assets

 -4.54 %

Current Assets

 3.08 %

Current Liabilities

 22.02 %

Trade Receivables

 2.55 %

Trade Payables

 69.68 %

Current Ratio

0.35

Certainly, let 's delve into a detailed point-wise explanation of the financial particulars for the year 2017:

1. EBITDA (Earnings before Interest, Taxes, Depreciation, and Amortization):

  The EBITDA margin, representing EBITDA as a percentage of revenue, is -80.49%. This indicates that the company 's operational profitability, excluding interest, taxes, and non-cash expenses, resulted in a negative margin. A negative EBITDA margin suggests challenges in generating sufficient operational income to cover fixed costs.

2. Net worth:

   The Net worth is reported as -23.30%, indicating that the company 's total assets are 23.30% less than its total liabilities. A negative net worth can be a cause for concern, as it implies potential financial instability and a higher degree of indebtedness.

3. Debt/Equity Ratio:

   The Debt/Equity Ratio stands at 3.88, suggesting that the company has a higher proportion of debt in its capital structure compared to equity. A higher ratio implies a relatively higher financial risk and could be a concern for investors and creditors.

4. Return on Equity (ROE):

   - The Return on Equity is -32.32%, indicating a negative return. This suggests that the company experienced a loss in shareholder value during the period. Negative ROE can be attributed to the company 's net loss and may signal financial challenges.

5. Total Assets:

   The Total Assets show a decrease of -0.06%, implying a slight reduction in the company 's overall assets during the year. A negative percentage indicates a contraction in total assets, which could result from asset write-downs, disposals, or other factors.

 6. Fixed Assets:

   Fixed Assets decreased by -4.54%, suggesting a reduction in long-term, non-current assets. This reduction may be attributed to asset impairments, sales, or a shift in the company 's capital expenditure strategy.

7. Current Assets:

    Current Assets increased by 3.08%, indicating a rise in short-term assets such as cash, receivables, and inventory. This could be a positive sign, contributing to the company 's liquidity and operational flexibility.

8. Current Liabilities:

   Current Liabilities increased significantly by 22.02%, representing the company 's short-term obligations. This substantial increase may raise liquidity concerns, as it indicates a higher need for short-term funds to meet immediate obligations.

9. Trade Receivables:

  Trade Receivables increased by 2.55%, suggesting a moderate growth in amounts owed to the company by its customers. Efficient management of receivables is crucial for maintaining healthy cash flow.

10. Trade Payables:

     Trade Payables increased significantly by 69.68%, indicating a substantial rise in amounts owed by the company to its suppliers. While this may provide short-term financing, careful management is needed to avoid liquidity issues.

11. Current Ratio:

   The Current Ratio is 0.35, indicating that the company may face challenges in meeting its short-term obligations with its current assets. A ratio below 1 suggests potential liquidity problems.

Annual Report

Sterling Biotech Ltd. Annual Report 2017

Download
Wealth Wisdom - WWIPL
Support Megha Support Neha